Ublituximab not checked
TG Therapeutics, Inc. · TG-1101 · TG1101
FollowEvery change as it happens, and a Monday email
Trials
8 active
28 in total · 7 in the EU
What this is
- How it works
- An antibody that marks B cells (a type of immune cell) for destruction. Used in blood cancers and autoimmune disease.CD20-directed Cytolytic Antibody FDA class
- How it’s given
- “Ublituximab (TG-1101) is a recombinant chimeric monoclonal antibody targeting CD20, available as a 25 mg/mL concentrate for intravenous use, supplied by TG Therapeutics, Inc.”In the company’s words, NCT04130997 on ClinicalTrials.gov
- Tested for
- Relapsing Multiple Sclerosis (3 trials), Relapsing Multiple Sclerosis (RMS), Multiple Sclerosis, Myasthenia Gravis, Schizophrenia
- Main trialPhase 3
- “The purpose of this study is to assess the pharmacokinetics of ublituximab when administered subcutaneously (SC) compared to intravenous (IV) administration in participants with RMS.”In the company’s words, NCT07211633 on ClinicalTrials.gov
- Other names
- TG-1101 · BRIUMVI · TG1101 · LFB-R603
Other drugs for Relapsing Multiple Sclerosis
- IMU-838Immunic AG · Phase 3
- CT-P53Celltrion · Phase 3
- ABP 692Amgen · Phase 3
- FrexalimabSanofi · Phase 3
- Peginterferon beta-1aBiogen · Phase 3
- PrivosegtorOculis · Phase 3
Coming up6
- 21 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Jul 2027Phase 2 trial completes · ClinicalTrials.gov
- 1 Jul 2028Phase 2 trial completes · ClinicalTrials.gov
- 12 Dec 2028Phase 2 trial completes · ClinicalTrials.gov
- 1 Jan 2030Phase 2/3 trial completes · ClinicalTrials.gov
- 31 May 2032Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials28
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 31 Oct 2026 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) | |
| Phase 3Recruiting | 21 Jan 2027 | Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | |
| Phase 3Active, not recruiting | 31 May 2032 | An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis | |
| Phase 2/3Recruiting | 1 Jan 2030 | Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis | |
| Phase 2Recruiting | 31 Jul 2027 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS) | |
| Phase 2Recruiting | 1 Jul 2028 | A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG) | |
| Phase 2Recruiting | 12 Dec 2028 | Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia | |
| Phase 3Completed | 1 Apr 2020 | Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) | |
| Phase 3Completed | 23 Jul 2020 | Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) | |
| Phase 3Completed | 4 Aug 2020 | Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) | |
| Phase 3Terminated | 22 Feb 2023 | Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia | |
| Phase 2/3Terminated | 31 May 2022 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma | |
| Phase 2/3Terminated | 20 Dec 2022 | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) | |
| Phase 2Completed | 27 Sep 2017 | Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis | |
| Phase 2Terminated | 16 May 2022 | Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma | |
| Phase 2Terminated | 22 May 2022 | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax | |
| Phase 2Terminated | 25 May 2022 | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials | |
| Phase 2Terminated | 26 May 2022 | A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304 | |
| Phase 2Completed | 11 Nov 2022 | An Extension of the TG1101-RMS201 Trial | |
| Phase 1/2Completed | May 2015 | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | |
| Phase 1/2Completed | Dec 2015 | Ublituximab + Ibrutinib in Select B-cell Malignancies | |
| Phase 1/2Terminated | 26 May 2022 | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL | |
| Phase 1Terminated | 7 Feb 2014 | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | |
| Phase 1Completed | 4 Nov 2021 | Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation | |
| Phase 1Completed | 21 Feb 2024 | Study of TG-1801 in Subjects With B-Cell Lymphoma | |
| Phase 1Terminated | 21 May 2024 | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies | |
| Phase 1Terminated | 12 Jun 2024 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | |
| Phase 1Authorised | not given | Pharmacokinetic/pharmacodynamic evaluation of ublituximab in patients with autoimmune diseases |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026